The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients

Annals of Oncology

Volumn 8, Issue 5, 1997, Pages 469-476

  Viale, G ^a,d   Maisonneuve, P ^a   Bonoldi, E ^b   Di Bacco, A ^a   Bevilacqua, P ^b   Panizzoni, G A ^b   Radaelli, U ^c   Gasparini, G ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b St Bortolo Medical Centre   (Italy)

^c St Paolo Hospital   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Bcl 2; Ovarian carcinomas; P53; Proliferative fraction

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; KI 67 ANTIGEN; PLATINUM; PROTEIN P53;

ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0030858479     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008253429700     Document Type: Article

References (49)

1. Thomas H, Nasim MM, Sarraf CE et al. Proliferating cell nuclear antigen (PCNA) immunostaining a prognostic factor in ovarian cancer? Br J Cancer 1995; 71: 357-62.
2. Cattoretti G. Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-63.
3. Bosari S, Viale G, Radaelli U et al. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993; 24: 1175-9.
4. Hartmann LC, Podratz KC, Keeney GL et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-9.
5. Henriksen R, Strang P, Wilander E et al. p53 expression in epithelial ovarian neoplasms: Relationships to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994; 53: 301-6.
6. van der Zee AGJ, Hollema H, Suurmeijer AJH et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70-8.
7. Levesque MA, Katsaros D, Yu H et al. Mutant p53 protein over-expression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995; 75: 1327-38.
8. Marks JR, Davidoff AM. Kerns BJ et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-84.
9. Sheridan E, Silcocks P, Smith J et al. p53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance. Eur J Cancer 1994; 30A: 1701-4.
10. Herod JJO, Eliopoulos AG. Warwick J et al. The prognostic-significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178-84.
11. Henriksen R, Wilander E, Oberg K, Expression and prognostic significance of bcl-2 in ovarian tumours. Br J Cancer 1995; 72: 1324-9.
12. Eliopoulos AG, Kerr DJ, Herod J et al. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and bcl-2. Oncogene 1995; 11; 1217-28.
13. Barnabei VM, Miller DS, Bauer KD et al. Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1990; 162: 1584-90.
14. Isola J, Kallioniemi OP, Korte JM et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 1990; 162: 295-301.
15. Henriksen R, Strang P. Backstrom T et al. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. Anti-Cancer Res 1994; 14: 603-8.
16. Kerns B-JM. Jordan PA, Faerman LL et al. Determination of proliferation index with MIB-I in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 1994; 101: 192-7.
17. Garzetti GG, Ciavattini A, Goteri G et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumours: Index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56: 169-74.
18. Hartmann LC, Sebo TJ, Kamel NA et al. Proliferating cell nuclear antigen in epithelial ovarian cancer: Relation to results at second-look laparatomy and survival. Gynecol Oncol 1992; 47: 191-5.
19. FIGO Cancer Committee. Staging announcement. Gynecol Oncol 1986; 25: 383.
20. Shepard JH. Revised FIGO staging for gynecological cancer. Br J Obstet Gynecol 1989; 96: 889-92.
21. Serov SF, Scully RE, Sobin LD. Histological typing of ovarian tumours. In International Histological Classification of Tumours No. 9. Geneva; World Health Organization 1973: 17-8.
22. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytoehem 1981; 29: 577-80.
23. Doglioni C, Dell'Orto P, Coggi G et al. Choroid plexus tumors. An immunocytochemical study with particular reference to the coexpression of intermediate filament proteins. Am J Pathol 1987; 127: 519-29.
24. Doglioni C, Dei Tos AP, Laurino L et al. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037-46.
25. Bosari S, Viale G, Roncalli M et al. p53 gene mutations. p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995; 147: 790-8.
26. Snedecor GW, Cochran WG. Statistical Methods, 8th ed. Ames, IA: Iowa State University Press 1989.
27. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichesler: Wiley 1995.
28. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley 1980.
29. Cox DR. Regression models and life tables. J R Stat Soc 1972; (B) 34: 187-220.
30. Rosman M, Hayden CL, Thiel RP et al. Prognostic indicators for poor risk epithelial ovarian carcinoma. Cancer 1994; 74: 1323-8.
31. Singleton TP, Perrone T, Oakley G et al. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 1994; 73: 1460-6.
32. Makar AP. Baekelandt M, Trope CG et al. The prognostic significance of residual disease. FlGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995; 56: 175-80.
33. Warwick J, Kehoe S, Earl H et al. Long-term follow-up of patients with advanced ovarian cancer in randomised clinical trials. Br J Cancer 1995; 72: 1513-7.
34. Righetti SC, Della Torre G, Pilotti S et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-93.
35. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
36. Williams GT, Smith CA. Molecular egulation of apoptosis: Genetic controls on cell death. Cell 1993; 74: 777-9.
37. Kastan MB, Canman CE, Lenaonard CJ. p53, cell cycle control and apoptosis. Cancer Metastasis Rev 1995; 14: 3-15.
38. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
39. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch 1995; 427: 229-41.
40. Kiyokawa T. Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994; 13: 311-8.
41. Jussila T, Stenback F. Cell proliferation markers and growth factors in ovarian cancers. Ann Med 1995; 27: 87-94.
42. Hockenbery D, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
43. Hockenbery D, Zutter M. Hickey W et al. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88: 6961-5.
44. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992; 80: 879-86.
45. Pezzella F, Turley H, Kuzu I et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-4.
46. Viale G, Roncalli M, Grimelius L et al. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 1995; 26: 945-50.
47. Gasparini G. Barbareschi M, Doglioni C et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995; 1: 189-98.
48. Bosari, S, Moneghini L, Graziani D et al. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas. Hum Pathol 1995; 26: 534-40.
49. Gasparini G, Bonoldi E, Viale G et al. Prognostic and predictive vulue of tumor angiogenesis in ovarian carcinomas. Int J Cancer 1996; 69: 205-11.